Loading clinical trials...
Loading clinical trials...
Butterfly glioblastomas (bGBM), defined as tumours crossing the midline to involve hemispheres bilaterally, have a dismal prognosis with a median survival of 3.3-6 months and only 9% of patients with ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
King's College Hospital NHS Trust
Collaborators
NCT06039709 · Recurrent Glioblastoma, Glioblastoma Multiforme, and more
NCT07225621 · Glioblastoma, GBM
NCT07100730 · Neoplastic Disease, Glioblastoma, and more
NCT07420543 · Brain Tumors and/or Solid Tumors Including, Glioblastoma, and more
NCT07391215 · Malignant Primary Gliomas, Glioblastoma Multiforme (GBM)
King's College NHS Foundation Trust
London
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions